Identification and Functional Characterization of pVHL-Dependent Cell Surface Proteins in Renal Cell Carcinoma

被引:42
作者
Boysen, Gunther [1 ]
Bausch-Fluck, Damaris [2 ]
Thoma, Claudio R. [3 ]
Nowicka, Anna M. [1 ]
Stiehl, Daniel P. [4 ]
Cima, Igor [3 ]
Van-Duc Luu [1 ]
von Teichman, Adriana [1 ]
Hermanns, Thomas [5 ]
Sulser, Tullio [5 ]
Ingold-Heppner, Barbara [1 ]
Fankhauser, Niklaus [3 ]
Wenger, Roland H. [4 ]
Krek, Wilhelm [3 ]
Schraml, Peter [1 ]
Wollscheid, Bernd [2 ]
Moch, Holger [1 ]
机构
[1] Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland
[2] ETH, Inst Mol Syst Biol, Zurich, Switzerland
[3] ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland
[4] Univ Zurich, Inst Physiol, Zurich, Switzerland
[5] Univ Zurich Hosp, Urol Clin, CH-8091 Zurich, Switzerland
来源
NEOPLASIA | 2012年 / 14卷 / 06期
关键词
TUMOR-SUPPRESSOR PROTEIN; CD10/NEUTRAL ENDOPEPTIDASE-24.11 PROMOTER; HIPPEL-LINDAU GENE; EXPRESSION; HYPOXIA; CD10; ALPHA; MUTATIONS; SUNITINIB; CANCER;
D O I
10.1596/neo.12130
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The identification of cell surface accessible biomarkers enabling diagnosis, disease monitoring, and treatment of renal cell carcinoma (RCC) is as challenging as the biology and progression of RCC is unpredictable. A hallmark of most RCC is the loss-of-function of the von Hippel-Lindau (pVHL) protein by mutation of its gene (VHL). Using the cell surface capturing (CSC) technology, we screened and identified cell surface N-glycoproteins in pVHL-negative and positive 786-O cells. One hundred six cell surface N-glycoproteins were identified. Stable isotope labeling with amino acids in cell culture-based quantification of the CSC screen revealed 23 N-glycoproteins whose abundance seemed to change in a pVHL-dependent manner. Targeted validation experiments using transcriptional profiling of primary RCC samples revealed that nine glycoproteins, including CD10 and AXL, could be directly linked to pVHL-mediated transcriptional regulation. Subsequent human tumor tissue analysis of these cell surface candidate markers showed a correlation between epithelial AXL expression and aggressive tumor phenotype, indicating that pVHL-dependent regulation of glycoproteins may influence the biologic behavior of RCC. Functional characterization of the metalloprotease CD10 in cell invasion assays demonstrated a diminished penetrating behavior of pVHL-negative 786-O cells on treatment with the CD10-specific inhibitor thiorphan. Our proteomic surfaceome screening approach in combination with transcriptional profiling and functional validation suggests pVHL-dependent cell surface glycoproteins as potential diagnostic markers for therapeutic targeting and RCC patient monitoring.
引用
收藏
页码:535 / +
页数:17
相关论文
共 48 条
[31]   Sunitinib efficacy against advanced renal cell carcinoma [J].
Motzer, Robert J. ;
Michaelson, M. Dror ;
Rosenberg, Jonathan ;
Bukowski, Ronald M. ;
Curti, Brendan D. ;
George, Daniel J. ;
Hudes, Gary R. ;
Redman, Bruce G. ;
Margolin, Kim A. ;
Wilding, George .
JOURNAL OF UROLOGY, 2007, 178 (05) :1883-1887
[32]   Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [J].
Motzer, Robert J. ;
Hutson, Thomas E. ;
Tomczak, Piotr ;
Michaelson, M. Dror ;
Bukowski, Ronald M. ;
Rixe, Olivier ;
Oudard, Stephane ;
Negrier, Sylvie ;
Szczylik, Cezary ;
Kim, Sindy T. ;
Chen, Isan ;
Bycott, Paul W. ;
Baum, Charles M. ;
Figlin, Robert A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :115-124
[33]   Sunitinib in patients with metastatic renal cell carcinoma [J].
Motzer, Robert J. ;
Rini, Brian I. ;
Bukowski, Ronald M. ;
Curti, Brendan D. ;
George, Daniel J. ;
Hudes, Gary R. ;
Redman, Bruce G. ;
Margolin, Kim A. ;
Merchan, Jaime R. ;
Wilding, George ;
Ginsberg, Michelle S. ;
Bacik, Jennifer ;
Kim, Sindy T. ;
Baum, Charles M. ;
Michaelson, M. Dror .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2516-2524
[34]  
Pournelle G. H., 1953, Journal of Mammalogy, V34, P133, DOI 10.1890/0012-9658(2002)083[1421:SDEOLC]2.0.CO
[35]  
2
[36]   VHL Gene Mutations and Their Effects on Hypoxia Inducible Factor HIFα: Identification of Potential Driver and Passenger Mutations [J].
Rechsteiner, Markus P. ;
von Teichman, Adriana ;
Nowicka, Anna ;
Sulser, Tullio ;
Schraml, Peter ;
Moch, Holger .
CANCER RESEARCH, 2011, 71 (16) :5500-5511
[37]   Targeted proteomic strategy for clinical biomarker discovery [J].
Schiess, Ralph ;
Wollscheid, Bernd ;
Aebersold, Ruedi .
MOLECULAR ONCOLOGY, 2009, 3 (01) :33-44
[38]   VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma [J].
Schraml, P ;
Struckmann, K ;
Hatz, F ;
Sonnet, S ;
Kully, C ;
Gasser, T ;
Sauter, G ;
Mihatsch, MJ ;
Moch, H .
JOURNAL OF PATHOLOGY, 2002, 196 (02) :186-193
[39]   Relevance of nuclear and cytoplasmic von Hippel Lindau protein expression for renal carcinoma progression [J].
Schraml, P ;
Hergovitz, A ;
Hatz, F ;
Amin, MB ;
Lim, SD ;
Krek, W ;
Mihatsch, MJ ;
Moch, H .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (03) :1013-1020
[40]   The type 1 CD10/neutral endopeptidase 24.11 promoter:: functional characterization of the 5′-untranslated region [J].
Sezaki, N ;
Ishimaru, F ;
Tabayashi, T ;
Kataoka, I ;
Nakase, K ;
Fujii, K ;
Kozuka, T ;
Nakayama, H ;
Harada, M ;
Tanimoto, M .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (01) :177-183